How should thrombocytopenia be evaluated (including differential diagnosis, diagnostic laboratory studies, and management) in a 48‑day‑old preterm infant (born at 29 weeks + 6 days, corrected gestational age 36 weeks) presenting with fever, hemoglobin 7.2 g/dL, and platelet count 87 × 10⁹/L?

Evaluation and Management of Thrombocytopenia in a 48-Day-Old Preterm Infant

In this 48-day-old preterm infant (corrected GA 36 weeks) with fever, anemia (Hb 7.2 g/dL), and moderate thrombocytopenia (platelets 87 × 10⁹/L), the most likely diagnosis is late-onset sepsis with or without necrotizing enterocolitis (NEC), and immediate management should include blood, urine, and CSF cultures followed by empiric broad-spectrum antibiotics while pursuing the diagnostic workup outlined below.

Pathophysiologic Differential Diagnosis

The timing (48 days old, corrected GA 36 weeks) and clinical presentation (fever + thrombocytopenia + anemia) strongly suggest late-onset thrombocytopenia (occurring after 72 hours of life), which has a distinct differential from early-onset disease 1, 2.

Primary Differential (by likelihood in this clinical context):

1. Sepsis-Associated Thrombocytopenia (Most Likely)

• Late thrombocytopenia is caused mainly by sepsis and NEC 2
• Mechanism: increased platelet consumption, endothelial damage, and bone marrow suppression
• Fever strongly supports infectious etiology
• Anemia may reflect hemolysis, bleeding, or chronic disease

2. Necrotizing Enterocolitis (NEC)

• Second most common cause of late thrombocytopenia in preterm infants 2
• May present with fever and systemic illness
• Assess for feeding intolerance, abdominal distension, bloody stools

3. Viral Infection

• CMV, HSV, enterovirus can cause thrombocytopenia 1
• May present with fever and cytopenias
• Consider if bacterial cultures negative

4. Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT) - Less Likely

• Typically presents at birth or within first 7 days with nadir platelet count <100 × 10⁹/L 3
• At 48 days, this is unlikely unless there was unrecognized early thrombocytopenia
• However, maternal ITP can cause persistent neonatal thrombocytopenia 4

5. Genetic/Inherited Thrombocytopenia

• Consider if thrombocytopenia persists without clear cause
• Bone marrow examination may show impaired megakaryopoiesis 4

Diagnostic Laboratory Studies

Immediate Studies (Stat):

Complete Blood Count with Differential and Peripheral Smear

• Confirm platelet count
• Assess for schistocytes (microangiopathy), platelet clumping (pseudothrombocytopenia)
• Evaluate other cell lines for pancytopenia
• Mean platelet volume (MPV): low in production defects, high in consumption 1

Sepsis Workup (Given Fever)

• Blood culture (before antibiotics)
• Urine culture by catheterization or suprapubic aspiration 5
• CSF analysis and culture (cell count, glucose, protein, Gram stain, culture) 5
• C-reactive protein and procalcitonin

Coagulation Studies

• PT/INR, aPTT, fibrinogen
• D-dimer if concerned about DIC or thrombotic microangiopathy
• Isolated thrombocytopenia rarely presents as hemorrhagic emergency 6

Secondary Studies (Based on Initial Results):

If Sepsis/NEC Suspected:

• Abdominal radiographs (if NEC concern)
• Viral PCR panel if bacterial cultures negative
• Consider CMV, HSV, enterovirus testing

If Immune Thrombocytopenia Suspected:

• Maternal history of ITP or autoimmune disease
• If FNAIT suspected (though unlikely at this age):
  • HPA genotyping of mother, father, and infant for HPA-1, -2, -3, -4, -5, -6, -9, -15 3
  • Maternal alloantibody testing using two different methods 3
  • Crossmatch with paternal platelets 3
  • Critical caveat: Delayed alloantibodies (anti-HPA-1, -3, -5) may appear weeks after birth, so repeat testing at 2-8 weeks if initially negative 3

If Thrombocytopenia Persists Without Clear Cause:

• Bone marrow examination to assess megakaryopoiesis 4
• Genetic testing for inherited thrombocytopenia syndromes
• Immunologic evaluation if IVIG-suboptimal response 4

Management Algorithm

Step 1: Immediate Stabilization and Infection Control

Hospitalization Required

• Facility with nurses/staff experienced in neonatal care 5
• Close monitoring for bleeding complications

Empiric Antibiotic Therapy

• Start immediately after cultures obtained
• Broad-spectrum coverage (e.g., ampicillin + gentamicin or cefotaxime)
• Adjust based on culture results and clinical response 5

Step 2: Platelet Transfusion Decision

Current Evidence Supports Restrictive Transfusion Strategy 1

Transfusion Thresholds:

• No bleeding, stable: Consider transfusion if platelets <20-30 × 10⁹/L
• Active bleeding or pre-procedure: Transfusion if platelets <50 × 10⁹/L
• Severe bleeding or neurosurgery: Target platelets >100 × 10⁹/L

Important Caveats:

• Platelet transfusions carry risks, especially in preterm neonates 2
• No proven efficacy in preventing bleeding when given prophylactically 2
• At 87 × 10⁹/L without bleeding, transfusion is NOT indicated unless invasive procedure planned

Contraindications to Platelet Transfusion:

• Do NOT transfuse if ITP or thrombotic thrombocytopenic purpura (TTP) suspected 7

Step 3: Cause-Specific Management

If Sepsis/NEC Confirmed:

• Continue antibiotics for appropriate duration based on organism and clinical response 5
• Discontinue antibiotics after 24-36 hours if cultures negative and infant clinically well 5
• Supportive care for NEC (NPO, TPN, surgical consultation if indicated)

If Maternal ITP/FNAIT Confirmed:

• IVIG 1 g/kg is first-line treatment 4
• May require multiple doses (up to 3 courses) 4
• Platelet transfusions should be HPA-compatible if FNAIT confirmed 3
• Critical: IVIG response may be suboptimal in preterm infants due to developmental FcRn biology 4
• Monitor platelet count closely; typically begins rising by day 14-19 in severe cases 4

If Viral Infection:

• Antiviral therapy if HSV or CMV confirmed
• Supportive care for enterovirus

Step 4: Monitoring and Follow-up

Serial Platelet Counts:

• Daily until stable upward trend
• More frequent if <30 × 10⁹/L or active bleeding

Clinical Monitoring:

• Assess for bleeding (petechiae, purpura, mucosal bleeding, intracranial hemorrhage)
• Head ultrasound if concern for intracranial bleeding, especially given prematurity

Reassessment at 24-36 Hours:

• Review culture results
• Assess clinical improvement (fever resolution, feeding tolerance)
• Adjust antibiotics based on sensitivities 5

Step 5: Disposition

Discontinue Antibiotics When:

1. Infant clinically well or improving
2. All cultures negative at 24-36 hours
3. No other infection requiring treatment 5

Discharge Criteria:

• Platelet count stable or rising
• No active bleeding
• Underlying cause identified and treated
• Adequate follow-up arranged

Common Pitfalls to Avoid

1. Over-transfusing platelets: Use restrictive thresholds; transfusions carry risks in neonates 1, 2

2. Missing FNAIT: Although unlikely at 48 days, maternal antibodies can appear late (2-8 weeks post-delivery) 3. If immune thrombocytopenia suspected, repeat maternal antibody testing.

3. Using EDTA samples for alloantibody testing: EDTA significantly reduces sensitivity of MAIPA assay 3

4. Delaying antibiotics: In febrile infant with thrombocytopenia, start empiric antibiotics immediately after cultures

5. Inadequate CSF evaluation: If LP not performed or uninterpretable, hospitalization in experienced facility is mandatory 5

6. Assuming single etiology: Preterm infants may have multifactorial thrombocytopenia (e.g., sepsis + impaired megakaryopoiesis + maternal antibodies) 4